Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yujin Wang

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Science Advances|October 12, 2023
Whole human-brain mapping of single cortical neurons for profiling morphological diversity and stereotypyXiaofeng Han, Shuxia Guo, Nan Ji, et al.
Journal of Medicinal Chemistry|August 17, 2016
Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus InfectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Cancer Cell|September 12, 2018
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRASShunsuke Kitajima, Hajime Asahina, Ting Chen, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV InhibitorsScott E Lazerwith, Gina Bahador, Eda Canales, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Science Advances|October 12, 2023
Whole human-brain mapping of single cortical neurons for profiling morphological diversity and stereotypyXiaofeng Han, Shuxia Guo, Nan Ji, et al.
Journal of Medicinal Chemistry|August 17, 2016
Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus InfectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Cancer Cell|September 12, 2018
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRASShunsuke Kitajima, Hajime Asahina, Ting Chen, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV InhibitorsScott E Lazerwith, Gina Bahador, Eda Canales, et al.
Pageof 14